Invenomic Investor holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Invenomic Fund Investor Class shares BIVRX
- NAV / 1-Day Return 15.96 / −1.18 %
- Total Assets 591.3M
-
Adj. Expense Ratio
2.490%
- Expense Ratio 3.290%
- Distribution Fee Level High
- Share Class Type No Load
- Category Long-Short Equity
- Investment Style Small Value
- Min. Initial Investment 5,000
- Status Limited
- TTM Yield 2.35%
- Turnover 197%
USD | NAV as of Jul 10, 2026 | 1-Day Return as of Jul 10, 2026, 12:58 AM GMT+0
Morningstar’s Analysis BIVRX
Will BIVRX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 8.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Us Dollar Broker | 72.86 | 707M | Cash and Equivalents |
First American Government Obligs X | 7.12 | 69M | Cash and Equivalents |
Australian Dollar | 4.27 | 41M | Cash and Equivalents |
Lyft Inc Class A | 3.15 | 31M | Technology |
Workday Inc Class A | 3.11 | 30M | Technology |
Fiserv Inc | 3.06 | 30M | Technology |
Salesforce Inc | 3.01 | 29M | Technology |
Global Payments Inc | 2.88 | 28M | Industrials |
Fidelity National Information Services Inc | 2.33 | 23M | Technology |
Ingredion Inc | 2.10 | 20M | Consumer Defensive |